1. Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

3. Introduction/Background

4. CV Risk in Patients With T2DM and No Prior MI Similar to Risk in People Without T2DM, but With Prior MI

5. Comparative Determinants of 4-Year CV Event Rates in Stable Outpatients at Risk of or With Atherothrombosis: REACH Registry

6. T2DM and Patients at CV Risk

7. BP Targets in the Context of T2DM Risk

8. Effect of Aspirin Therapy on Primary Prevention of Major CV Events: Results of a Meta-Analysis

9. Safety of Glucose-Lowering Agents in T2DM

10. DPP-4 Inhibitors: Topline Clinical Trial Results

11. GLP-1 RAs: Topline Clinical Trial Results

12. SGLT2 Inhibitors: Clinical Trial Results

13. AEs Associated With TZDs in T2DM

14. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

15. Potential Limitations of T2DM CV Safety Outcomes Trials

16. SAVOR-TIMI 53 (Saxagliptin): Hospitalization for HF

17. EXAMINE (Alogliptin): Hospitalization for HF

18. TECOS (Sitagliptin): Hospitalization for HF

19. ELIXA (Lixisenatide): Primary Outcome CV Death, Nonfatal MI, Nonfatal Stroke, or Hospitalization for UA

20. LEADER: Primary Outcome*

21. EMPA-REG OUTCOME: Trial Design

22. EMPA-REG Primary Outcome (3-Point MACE): CV Death, Non-Fatal MI, or Non-Fatal Stroke

23. EMPA-REG: Results for CV Death

24. EMPA-REG Microvascular Outcomes: Renal Protection

25. EMPA-REG: Hospitalization for Heart Failure

26. Potential Mechanisms for CV Benefit Associated With Empagliflozin

27. Potential Pathways Linking SGLT2 Inhibitor and Reduced Risk of Hospitalization for HF

28. EMPA-REG Outcomes: Class Effect or Agent Specific?

29. CDA Treatment Guidelines: 2016 Interim Update SGLT2 Inhibition

30. Conclusions

31. Abbreviations

32. Abbreviations (cont)